Key result
ARBs achieve the lowest 4-year discontinuation rate among antihypertensives at ~58%.
Why the study?
Blood pressure control rates remain unsatisfactory despite widespread diagnosis and treatment of hypertension, with unclear reasons for poor long-term persistence with antihypertensive therapies in primary care.
Answers are grounded in this paper and cite their sources.
Despite major efforts directed worldwide to diagnose and treat hypertension, the blood pressure control rate is still unsatisfactory [1]. This is true even in industrialized countries where hypertensive patients have easy access to health care [2]. Why is it so difficult to normalize blood pressure in the community? Beyond the treatment cost and reimbursement issue, several reasons may be advanced: (i) the ‘low’ target blood pressures currently recommended are difficult to reach; (ii) many doctors are not convinced that strict blood pressure control is required to afford optimal cardiovascular and renal protection; and (iii) hypertensive patients are poorly motivated to adhere with a lifelong treatment if the prescribed drug regimen impairs their quality of life [3,4]. Recent interventional event-based trials have shown that it is indeed possible to normalize blood pressure in most hypertensive patients using various mono- and combination therapies [5,6]. The same trials have also documented the benefits derived from a tight blood pressure control. At a time when evidence-based medicine is becoming more and more important in driving therapeutic decisions, the data in the field of hypertension therefore exist to motivate doctors to adhere to hypertension guidelines. In this issue of the journal, Burke et al. [7] evaluated the discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients. They had access to the UK General Practice Research Database, which allowed them to analyse prescription refills in a cohort of patients receiving a first prescription for a blood pressure-lowering drug. Several other investigators have previously used the same approach to assess persistence with antihypertensive therapy [8–15]. Why is this study of special interest? Principally, because it reflects the experience accumulated in very large number of patients (n = 109 454) who were followed for up to 9 years. Second, the findings are representative of what happens in primary care because only general practitioners (GPs) were involved. The GPs were apparently free, during the 1991–2001 survey period, to choose any drug class to start antihypertensive therapy, and all patients had free access to medical care through the UK National Health Service. Among the main classes of blood pressure-lowering agents, the cumulative incidence of discontinuation over the first 4 years of follow-up was the smallest for AT1-receptor blockers (57.8%), followed by angiotensin-converting enzyme (ACE) inhibitors (60.4%), calcium antagonists (64.7%), β-blockers (66.7%) and thiazide diuretics (69.3%). In a previous persistence study of similar duration involving 15 175 hypertensive patients in the USA, interruption of treatment was seen in 49.1% of patients receiving an AT1-receptor blocker, versus 53.5, 59.3, 65.3 and 83.6% of those who were on a ACE inhibitor, a calcium antagonist, a β-blocker or a thiazide diuretic, respectively [9]. The different classes of antihypertensive agents ranked similarly in the two surveys, but patients in the UK tended to stay longer on the initial medication than those in the USA. Persistence with antihypertensive therapy can be regarded as an indicator of long-term compliance with treatment [16]. Unfortunately, the reasons for discontinuating drug therapy were not assessed in the present study. Different factors might play a role. The occurrence of adverse effects during treatment probably represents the primary concern for the patient. Any impairment in quality of life may lead to poor compliance and treatment discontinuation [17,18]. Blockers of the renin–angiotensin system display a better tolerability profile than other antihypertensive agents, especially when given at higher doses [19]. This might account for the better persistence observed with AT1-receptor blockers and ACE inhibitors compared with calcium antagonists, β-blockers and thiazide diuretics. Having a normal blood pressure under treatment is motivating for the patient and is expected to have a positive impact on the continuation rate. Whether the quality of blood pressure control was a determinant of the discontinuation was not evaluated. However, in terms of antihypertensive efficacy, the different classes of antihypertensive agents have repeatedly been shown to be equally effective when administered as monotherapy [19]. It is therefore unlikely that some medications were discontinued more frequently than others because they normalized blood pressure in fewer patients. Notably, whatever the initial drug chosen, approximately 44% of patients discontinued their first-ever antihypertensive drug and switched to another antihypertensive drug class. In the remaining patients, no prescription for a blood pressure-lowering agent was issued within the 90 days following the date the last prescription expired, indicating real therapy interruption. These hypertensive patients not on treatment anymore were certainly at an increased cardiovascular risk considering this high percentage of treatment interruptions, and thus it is important to urge primary care doctors to monitor newly-diagnosed hypertensive patients regularly. The drug regimen should be adjusted when required not only to normalize blood pressure, but also to preserve as much as possible the patients' quality of life. The ultimate goal of antihypertensive therapy is to normalize blood pressure over a period of years. Persistence with antihypertensive therapy is therefore critical and can be achieved only if doctors are motivated and patients are satisfied.
No takes yet. Share an insight, caveat, or question.
Waeber et al. (2006) conducted an editorial in hypertension (n=109,454). Antihypertensive drug classes vs. Different antihypertensive classes was evaluated on cumulative incidence of discontinuation over the first 4 years of follow-up. Among newly diagnosed hypertensive patients, the 4-year cumulative incidence of discontinuation was lowest for AT1-receptor blockers and highest for thiazide diuretics.
Synapse has enriched 10 related papers. Consider them for comparative context: